LTO1 and hepatocellular carcinoma: Based on these findings, we propose that ORAOV1-associated activation of IL-17 signaling may drive ECM remodeling, TME dysfunction, impaired channel activity, and broad therapeutic resistance in HCC (Fig. 6).